Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2016 | Side effects of idelalisib in CLL and how to manage them

Jennifer Brown • 3 Jun 2016
ASCO 2016
Chronic Lymphocytic Leukemia Idelalisib

Jennifer Brown, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA outlines the side effects that may occur in chronic lymphocytic leukemia (CLL) patients treated with idealisib and how to manage them. Side effects to look out for include neutropenia, bacterial infections, immunologic toxicitiy and diarrhea colitis.
Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.

More from Jennifer Brown

Complex karyotype, but not isolated TP53 mutation, predicts OS in CLL in the era of targeted therapy 1:44
Complex karyotype, but not isolated TP53 mutation, predicts OS in CLL in the era of targeted therapy
Jennifer Brown • 10 Dec 2024
Primary endpoint evaluation of a Phase II study of AVO in previously untreated high-risk CLL 1:16
Primary endpoint evaluation of a Phase II study of AVO in previously untreated high-risk CLL
Jennifer Brown • 10 Dec 2024
Interim results of AMPLIFY: AV/AVO versus chemoimmunotherapy for first-line treatment of CLL 2:48
Interim results of AMPLIFY: AV/AVO versus chemoimmunotherapy for first-line treatment of CLL
Jennifer Brown • 10 Dec 2024
Assessing cardiovascular tolerability of zanubrutinib vs ibrutinib in pts with B-cell malignancies 1:09
Assessing cardiovascular tolerability of zanubrutinib vs ibrutinib in pts with B-cell malignancies
Jennifer Brown • 14 Jun 2024

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals